NanJing Pharmaceutical Co Ltd
SSE:600713
Intrinsic Value
Nanjing Pharmaceutical Co., Ltd. engages in the service of pharmaceutical distribution. [ Read More ]
The intrinsic value of one
NanJing Pharmaceutical Co Ltd
stock under the Base Case scenario is
12.93
CNY.
Compared to the current market price of 4.67 CNY,
NanJing Pharmaceutical Co Ltd
is
Undervalued by 64%.
NanJing Pharmaceutical Co Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
NanJing Pharmaceutical Co Ltd's market capitalization is 6B CNY.
NanJing Pharmaceutical Co Ltd stock price is 4.67 CNY.
NanJing Pharmaceutical Co Ltd stock price (4.67 CNY) is 64% less than its Intrinsic Value (12.93 CNY).
NanJing Pharmaceutical Co Ltd stock (2.93 CNY) is 37% less than its price (4.67 CNY). Open DCF Valuation
NanJing Pharmaceutical Co Ltd stock price (4.67 CNY) is 80% less than its Relative Value (22.93 CNY). Open Relative Valuation
NanJing Pharmaceutical Co Ltd has upside potential of 148% compared to the average analyst price target.
Open Wall St Estimates
NanJing Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
NanJing Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 4% to 5%.
NanJing Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 10% to 9%.
NanJing Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
NanJing Pharmaceutical Co Ltd's Revenue has grown by 8% over the past 12 months.
NanJing Pharmaceutical Co Ltd's Altman Z-Score is equal to 2.41.
NanJing Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
NanJing Pharmaceutical Co Ltd's long-term assets (33B CNY) exceed its long-term liabilties (27B CNY).
NanJing Pharmaceutical Co Ltd's short-term assets (31B CNY) exceed its short-term liabilties (24B CNY).
NanJing Pharmaceutical Co Ltd's D/E (Debt to Equity) is equal to 1.34.
NanJing Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
NanJing Pharmaceutical Co Ltd's Revenue has been growing by 11% per year for the last 3 years.
NanJing Pharmaceutical Co Ltd has negative Free Cash Flow for the last twelve months.
NanJing Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
NanJing Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
NanJing Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
NanJing Pharmaceutical Co Ltd has positive Net Debt. This means that the company has more debt (8B CNY) than cash and short-term investments (2B CNY).
Valuation Backtest
NanJing Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
NanJing Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
NanJing Pharmaceutical Co Ltd
Balance Sheet Decomposition
NanJing Pharmaceutical Co Ltd
| Current Assets | 30.8B |
| Cash & Short-Term Investments | 2.4B |
| Receivables | 23.1B |
| Other Current Assets | 5.4B |
| Non-Current Assets | 2.4B |
| Long-Term Investments | 327.9m |
| PP&E | 1.5B |
| Intangibles | 290.3m |
| Other Non-Current Assets | 274.4m |
| Current Liabilities | 23.6B |
| Accounts Payable | 7B |
| Accrued Liabilities | 163.1m |
| Short-Term Debt | 6.2B |
| Other Current Liabilities | 10.2B |
| Non-Current Liabilities | 3.4B |
| Long-Term Debt | 2.2B |
| Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
NanJing Pharmaceutical Co Ltd
|
Revenue
|
53.3B
CNY
|
|
Cost of Revenue
|
-50.1B
CNY
|
|
Gross Profit
|
3.3B
CNY
|
|
Operating Expenses
|
-1.8B
CNY
|
|
Operating Income
|
1.5B
CNY
|
|
Other Expenses
|
-928.4m
CNY
|
|
Net Income
|
565.7m
CNY
|
Free Cash Flow Analysis
NanJing Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
NanJing Pharmaceutical Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
NanJing Pharmaceutical Co Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
NanJing Pharmaceutical Co Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
NanJing Pharmaceutical Co Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
NanJing Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
NanJing Pharmaceutical Co Ltd
is 11.6 CNY
.
Shareholder Return
Price
NanJing Pharmaceutical Co Ltd
| Average Annual Return | 2.67% |
| Standard Deviation of Annual Returns | 11.12% |
| Max Drawdown | -35% |
| Market Capitalization | 6B CNY |
| Shares Outstanding | 1 310 231 012 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
NanJing Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Nanjing Pharmaceutical Co., Ltd. engages in the service of pharmaceutical distribution. The company is headquartered in Nanjing, Jiangsu and currently employs 5,062 full-time employees. The firm's principal businesses include the pharmaceutical wholesale, pharmaceutical retail, pharmaceutical-Internet + business, as well as the pharmaceutical third-party logistics services. The firm mainly conducts its business in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
NanJing Pharmaceutical Co Ltd
stock under the Base Case scenario is
12.93
CNY.
Compared to the current market price of 4.67 CNY,
NanJing Pharmaceutical Co Ltd
is
Undervalued by 64%.
You don't have any saved screeners yet
